Advertisement

Molekulare Reaktionsformen und bildgebende Diagnostik gastro-intestinaler Stromatumoren auf die Therapie mit Tyrosinkinase Inhibitor Imatinib (STI571)

  • Peter Hohenberger
  • U. Schneider
  • P. Reichardt
  • D. Pink
  • C. Stroszcynski
Conference paper
Part of the Deutsche Gesellschaft für Chirurgie book series (DTGESCHIR, volume 31)

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, and are generally resistant to chemotherapy and radiation. Most GISTs express the KIT receptor tyrosine kinase protein (CD117) and the signal transduction inhibitor imatinib mesylate can be used for treatment. Immunohistochemic analysis of biopsies from humans during treatment with imatinib were analysed and revealed widespread hemorrhagia but no necrosis. Proliferative cell fraction decreased to nearly zero whereas expression of CD117 remained unchanged. Gadolinium-enhanced MRI allowed us to follow the changes in tumor architecture with cystic areas developing at the center in conjunction with a rim of well-perfused parenchyma only, while no major decrease in size developed. Functional imaging by MRI or PET is required to adequately assess the efficacy of tyrosine kinase inhibitor treatment of GISTs.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118–8121PubMedGoogle Scholar
  2. 2.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI57l in a patient with a metastatic gastrointestinal stromal tumor. N. Engl J Med 344: 1052 - 1056PubMedCrossRefGoogle Scholar
  3. 3.
    Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD (2001) STI57l inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054 - 5058PubMedCrossRefGoogle Scholar
  4. 4.
    Blanke CD, von Mehren M, Joensuu H, et al. (2001) Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI157, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit (CD117). Proc Am Soc Clin Oncol 20: A– 1Google Scholar
  5. 5.
    Van Oosterom AT, Judson I, Verweij J, et al. (2001) STI 571, an active drug in metastatic gastro intestinal stromal tumors (GIST), an EORTC phase I study. Proc Am Soc Clin Oncol 20: A–2Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • Peter Hohenberger
    • 1
    • 5
  • U. Schneider
    • 2
  • P. Reichardt
    • 3
  • D. Pink
    • 3
  • C. Stroszcynski
    • 4
  1. 1.Klinik für Chirurgie und Chirurgische OnkologieGermany
  2. 2.Pathologisches InstitutGermany
  3. 3.Klinik für Hämatologie, Onkologie, und TumorimmunologieGermany
  4. 4.Strahlenklinik, Universitätsklinikum Charité, Campus Berlin-Buch, Robert Rössle KlinikHumboldt Universität BerlinGermany
  5. 5.Klinik für Chirurgie und Chirurgische OnkologieUniversitätsklinikum Charité, Robert-Rössle-Klinik am Max-Delbriick Centrum für Molekulare MedizinBerlinGermany

Personalised recommendations